Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy

Table 1 Patient, tumor and treatment characteristics

Characteristic		n	Percent
Age (yr), median	54 (range, 32-75)
Sex	Male	44	86.3
	Female	7	13.7
Viral type	B	44	86.3
	C	4	7.8
	NBNC	3	5.9
Child-Pugh class	A	49	96.1
	B	2	3.9
Modified UICC stage	II	4	7.8
	III	32	62.7
	IV	15	29.5
BCLC stage	A	14	27.5
	B	12	23.5
	C	25	49.0
PVT	No	31	60.8
	Yes	20	39.2
Multiplicity	No	25	49.0
	Yes	26	51.0
Tumor size in cm, median		8.5 (range, 1.0-19.6)
AFP (IU/mL), median	141.9 (range, 1.53-83000)
PIVKA-II (mAU/mL), median	600 (range, 12-2000)
Treatment-naïve	Yes	29	56.9
	No	22	43.1
Total dose of RT (Gy), median		50.4 (range, 45-64.8)

NBNC: Non-B non-C; UICC: International Union Against Cancer; BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: Radiotherapy.